These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 34751121)

  • 1. Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India.
    Puri R; Mehta V; Iyengar SS; Srivastava P; Yusuf J; Pradhan A; Pandian JD; Sharma VK; Renjen PN; Muruganathan A; Krishnan M; Srinivasan AV; Shetty S; Narasingan SN; Nair DR; Bansal M; Prabhakar D; Varma M; Paliwal VK; Kapoor A; Mukhopadhyay S; Mehrotra R; Patanwala RM; Aggarwal R; Mahajan K; Kumar S; Bardoloi N; Pareek KK; Manoria PC; Pancholia AK; Nanda R; Wong ND; Duell PB
    Curr Vasc Pharmacol; 2022; 20(2):134-155. PubMed ID: 34751121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Patients for Nonstatin Therapy.
    Robinson JG; Watson KE
    Rev Cardiovasc Med; 2018; 19(S1):S1-S8. PubMed ID: 30207552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
    Puri R; Mehta V; Duell PB; Nair D; Mohan JC; Yusuf J; Dalal JJ; Mishra S; Kasliwal RR; Agarwal R; Mukhopadhyay S; Wardhan H; Khanna NN; Pradhan A; Mehrotra R; Kumar A; Puri S; Muruganathan A; Sattur GB; Yadav M; Singh HP; Agarwal RK; Nanda R
    J Clin Lipidol; 2020; 14(2):e1-e13. PubMed ID: 32089456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
    Mehta V; Puri R; Duell PB; Iyengar SS; Wong ND; Yusuf J; Mukhopadhyay S; Pradhan A; Muruganathan A; Wangnoo SK; Kapoor D; Rastogi A; Tiwaskar MH; Mahajan K; Narasingan SN; Agarwala R; Bordoloi N; Soumitra K; Chakraborty R; Shetty S; Saboo B; Khan A; Prabhakar D; Khanna NN; Mehta A; Bansal M; Kasliwal R; Mehrotra R; Chag M; Sheikh A; Sattur GB; Manoria PC; Pareek KK; Pancholia AK; Melinker RP; Nanda R; Kalra D
    J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing dyslipidaemia in patients with chronic kidney disease.
    Mehta A
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S90-S92. PubMed ID: 38278323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid management beyond the guidelines.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):384-389. PubMed ID: 31669499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
    Chang Y; Eom S; Kim M; Song TJ
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.